J
Jan P. van Meerbeeck
Researcher at University of Antwerp
Publications - 282
Citations - 16356
Jan P. van Meerbeeck is an academic researcher from University of Antwerp. The author has contributed to research in topics: Lung cancer & Mesothelioma. The author has an hindex of 53, co-authored 254 publications receiving 13009 citations. Previous affiliations of Jan P. van Meerbeeck include Ghent University Hospital & Ghent University.
Papers
More filters
Journal ArticleDOI
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Peter Goldstraw,Kari Chansky,John Crowley,Ramón Rami-Porta,Hisao Asamura,Wilfried Ernst Erich Eberhardt,Andrew G. Nicholson,Patti A. Groome,Alan Mitchell,Vanessa Bolejack,David Ball,David G. Beer,Ricardo Beyruti,Frank C. Detterbeck,Wilfried Eberhardt,John G. Edwards,Françoise Galateau-Salle,Dorothy Giroux,Fergus V. Gleeson,James Huang,Catherine Kennedy,Jhingook Kim,Young Tae Kim,Laura Kingsbury,Haruhiko Kondo,Mark Krasnik,Kaoru Kubota,Antoon Lerut,Gustavo Lyons,Mirella Marino,Edith M. Marom,Jan P. van Meerbeeck,Takashi Nakano,Anna K. Nowak,Michael D Peake,Thomas W. Rice,Kenneth E. Rosenzweig,Enrico Ruffini,Valerie W. Rusch,Nagahiro Saijo,Paul Van Schil,Jean-Paul Sculier,Lynn Shemanski,Kelly G. Stratton,Kenji Suzuki,Yuji Tachimori,Charles F. Thomas,William D. Travis,Ming-Sound Tsao,Andrew T. Turrisi,Johan Vansteenkiste,Hirokazu Watanabe,Yi-Long Wu,Paul Baas,Jeremy J. Erasmus,Seiki Hasegawa,Kouki Inai,Kemp H. Kernstine,Hedy L. Kindler,Lee M. Krug,Kristiaan Nackaerts,Harvey I. Pass,David C. Rice,Conrad Falkson,Pier Luigi Filosso,Giuseppe Giaccone,Kazuya Kondo,Marco Lucchi,Meinoshin Okumura,Eugene H. Blackstone,F. Abad Cavaco,E. Ansótegui Barrera,J. Abal Arca,I. Parente Lamelas,A. Arnau Obrer,R. Guijarro Jorge,D. Ball,G.K. Bascom,A. I. Blanco Orozco,M. A. González Castro,M.G. Blum,D. Chimondeguy,V. Cvijanovic,S. Defranchi,B. de Olaiz Navarro,I. Escobar Campuzano,I. Macía Vidueira,E. Fernández Araujo,F. Andreo García,Kwun M. Fong,G. Francisco Corral,S. Cerezo González,J. Freixinet Gilart,L. García Arangüena,S. García Barajas,P. Girard,Tuncay Göksel,M. T. González Budiño,G. González Casaurrán,J. A. Gullón Blanco,J. Hernández Hernández,H. Hernández Rodríguez,J. Herrero Collantes,M. Iglesias Heras,J. M. Izquierdo Elena,Erik Jakobsen,S. Kostas,P. León Atance,A. Núñez Ares,M. Liao,M. Losanovscky,G. Lyons,R. Magaroles,L. De Esteban Júlvez,M. Mariñán Gorospe,Brian C. McCaughan,Catherine J. Kennedy,R. Melchor Íñiguez,L. Miravet Sorribes,S. Naranjo Gozalo,C. Álvarez de Arriba,M. Núñez Delgado,J. Padilla Alarcón,J. C. Peñalver Cuesta,Jongsun Park,H. Pass,M. J. Pavón Fernández,Mara Rosenberg,Enrico Ruffini,V. Rusch,J. Sánchez de Cos Escuín,A. Saura Vinuesa,M. Serra Mitjans,Trond Eirik Strand,Dragan Subotic,S.G. Swisher,Ricardo Mingarini Terra,Charles R. Thomas,Kurt G. Tournoy,P. Van Schil,M. Velasquez,Y.L. Wu,K. Yokoi +142 more
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.
Journal ArticleDOI
Small Cell Lung Cancer
TL;DR: Combination chemotherapy, generally platinum-based plus etoposide or irinotecan, is the mainstay first-line treatment for metastatic small-cell lung cancer as discussed by the authors.
Journal ArticleDOI
Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non–Small-Cell Lung Cancer
Jan P. van Meerbeeck,Gijs W. P. M. Kramer,Paul Van Schil,Catherine Legrand,Egbert F. Smit,Franz M.N.H. Schramel,Vivianne C. G. Tjan-Heijnen,Bonne Biesma,C. Debruyne,Nico van Zandwijk,Ted A.W. Splinter,Giuseppe Giaccone +11 more
TL;DR: In selected patients with pathologically proven stage IIIA-N2 NSCLC and a response to induction chemotherapy, surgical resection did not improve overall or progression-free survival compared with radiother- apy, and radiotherapy should be considered the preferred locoregional treatment for these patients.
Journal ArticleDOI
Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
Jan P. van Meerbeeck,Rabab Gaafar,Christian Manegold,Rob J. van Klaveren,Eric Van Marck,Mark Vincent,Catherine Legrand,Andrew Bottomley,C. Debruyne,Giuseppe Giaccone +9 more
TL;DR: It is confirmed that a combination of cis platin and an antifolate is superior to cisplatin alone in patients with MPM, without harmful effect on HRQOL.
Journal ArticleDOI
Mediastinoscopy vs Endosonography for Mediastinal Nodal Staging of Lung Cancer: A Randomized Trial
Jouke T. Annema,Jan P. van Meerbeeck,Robert C. Rintoul,Christophe Dooms,Ellen Deschepper,Olaf M. Dekkers,Paul De Leyn,Jerry Braun,Nicholas Carroll,Marleen Praet,Frederick de Ryck,Johan Vansteenkiste,Frank Vermassen,Michel I.M. Versteegh,Maud Veselic,Andrew G. Nicholson,Klaus F. Rabe,Kurt G. Tournoy +17 more
TL;DR: Among patients with (suspected) NSCLC, a staging strategy combining endosonography and surgical staging compared with surgical staging alone resulted in greater sensitivity for mediastinal nodal metastases and fewer unnecessary thoracotomies.